VENTANA MET (SP44) RxDx Testing Sites

The VENTANA MET (SP44) RxDx Assay is the latest addition to Roche’s market-leading portfolio of IHC/ISH companion diagnostics designed to provide critical insights that enable more informed clinical decisions and improve patient outcomes. Detecting MET is key to determining eligibility for Emrelis™ (telisotuzumab vedotin-tllv).

Find testing sites across the U.S. that are accepting patient samples here.